J&J Risperdal Consta “non-approvable”
Executive Summary
J&J will discuss FDA concerns about pre-clinical data for injectable long-acting antipsychotic Risperdal Consta (risperidone) following receipt of "non-approvable" letter. J&J filed the NDA Aug. 31, 2001...